Friday, 29 September 2017

BioLargo’s Medical Subsidiary Files 510(k) with FDA for its Novel Wound Care Technology

Westminster, CA (Uptick Newswire – September 28, 2017) – BioLargo, Inc. (OTCQB:BLGO), a sustainable science and technology company that delivers practical solutions for clean water, clean air, and advanced wound care, announced today its subsidiary Clyra Medical Technologies had submitted to the Food & Drug Administration an application for premarket notification under Section 510(k) of the Food, Drug, and Cosmetic Act. By statute, Clyra must wait 90 days prior to going to market while the FDA evaluates the submission and determines whether to grant it clearance.







BioLargo also announced that the new technology and related data will be exhibited at the Symposium on Advanced Wound Care/Fall (SAWC/Fall), October 20 – 22, 2017, in Las Vegas, Nevada (http://www.sawc.net/fall/). The semi-annual SAWC meeting is the premier interdisciplinary wound care program and the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, researchers, and scientists are expected to attend the 2017 SAWC/Fall meeting.
Clyra Medical President Steve Harrison commented, “In keeping with BioLargo’s mission, our advanced wound care products have an important contribution to Make Life Better for those suffering with a wide variety of wounds. Our products are safe, gentle and effective, and as such, we believe their role in infection control, chronic wound management, and regenerative skin therapy are important and valuable. We hope this FDA submission is the first of many that will allow us to bring Clyra products to the Advanced Wound Care market.”
President & CEO of BioLargo, Dennis P. Calvert commented, “This very important milestone is another example of our dedication to build value for our shareholders. This project has required an army of supporters, investors, and a highly qualified technical team to make our vision for these products a reality. Through Clyra Medical we will serve others in a very high value market and we believe these platform products will play an important role in health care for decades to come.”
About BioLargo, Inc.
BioLargo, Inc. is a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air and advanced wound care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com) features an exceptional team of experienced specialists dedicated to integrity, reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous contaminants in water in a fraction of the time and cost of current technologies. Its odor division features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that that contends with malodors, VOC’s or similar air quality related problems. Its personal care product division features products in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). Its medical division (www.ClyraMedical.com) focuses on advanced wound care management, featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control and regenerative tissue therapy. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc (www.ClarionWater.com).                    
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2
Source: Uptick Newswire

No comments:

Post a Comment

widget